LOAMS
Lombard Odier Asset Management (Switzerland) Portfolio holdings
AUM
$1.98B
1-Year Return
25.93%
This Quarter Return
+9.74%
1 Year Return
+25.93%
3 Year Return
+103.45%
5 Year Return
+160.5%
10 Year Return
+469.02%
AUM
$1.5B
AUM Growth
+$610M
(+69%)
Cap. Flow
+$517M
Cap. Flow
% of AUM
34.54%
Top 10 Holdings %
Top 10 Hldgs %
20.38%
Holding
396
New
274
Increased
36
Reduced
41
Closed
8
Top Buys
| 1 |
GoodRx Holdings
GDRX
|
$29.8M |
| 2 |
Thor Industries
THO
|
$26.9M |
| 3 |
Labcorp
LH
|
$23.2M |
| 4 |
Intellia Therapeutics
NTLA
|
$22.7M |
| 5 |
LHCG
LHC Group LLC
LHCG
|
$21M |
Top Sells
| 1 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
$19.6M |
| 2 |
InMode
INMD
|
$19M |
| 3 |
BEAT
BioTelemetry, Inc.
BEAT
|
$18M |
| 4 |
Futu Holdings
FUTU
|
$12.9M |
| 5 |
DexCom
DXCM
|
$11.4M |
Sector Composition
| 1 | Healthcare | 45.52% |
| 2 | Consumer Discretionary | 13.92% |
| 3 | Financials | 12.31% |
| 4 | Technology | 6.99% |
| 5 | Communication Services | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Allogene Therapeutics
ALLO
$237M
| $18.9M | 1.26% |
+536,738
| New | +$18.9M |
|
27
UnitedHealth
UNH
$278B
| $18.9M | 1.25% |
50,801
| – | – |
|
28
Halozyme
HALO
$8.69B
| $18.8M | 1.24% |
450,000
-20,000
| -4% | -$834K |
|
29
10x Genomics
TXG
$1.65B
| $17.9M | 1.19% |
+99,061
| New | +$17.9M |
|
30
NeoGenomics
NEO
$1.03B
| $17.5M | 1.16% |
+362,842
| New | +$17.5M |
|
31
Equity Lifestyle Properties
ELS
$11.7B
| $17.2M | 1.14% |
270,000
| – | – |
|
32
Medifast
MED
$154M
| $16.9M | 1.12% |
80,000
-30,000
| -27% | -$6.35M |
|
33
iShares MSCI India ETF
INDA
$9.25B
| $16.9M | 1.12% |
401,200
-12,000
| -3% | -$506K |
|
34
Moderna
MRNA
$9.26B
| $16.7M | 1.11% |
+127,704
| New | +$16.7M |
|
35
Natera
NTRA
$23B
| $16.6M | 1.1% |
+163,278
| New | +$16.6M |
|
36
Apellis Pharmaceuticals
APLS
$3.48B
| $16.3M | 1.08% |
+379,395
| New | +$16.3M |
|
|
TRHC
37
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| $15.9M | 1.05% |
+344,334
| New | +$15.9M |
|
38
Trip.com Group
TCOM
$46.8B
| $15.6M | 1.03% |
392,865
-94,340
| -19% | -$3.74M |
|
39
TAL Education Group
TAL
$6.26B
| $15.3M | 1.01% |
283,348
+75,268
| +36% | +$4.05M |
|
|
IMGN
40
DELISTED
Immunogen Inc
IMGN
| $15M | 0.99% |
+1,849,772
| New | +$15M |
|
41
Apple
AAPL
$3.52T
| $14.6M | 0.97% |
119,630
+351
| +0.3% | +$42.9K |
|
42
Neurocrine Biosciences
NBIX
$13.6B
| $14.6M | 0.97% |
+149,864
| New | +$14.6M |
|
|
GTHX
43
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $14.5M | 0.96% |
+601,591
| New | +$14.5M |
|
|
DRNA
44
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $13.5M | 0.89% |
+526,058
| New | +$13.5M |
|
45
Twist Bioscience
TWST
$1.52B
| $13.3M | 0.88% |
+107,403
| New | +$13.3M |
|
|
MDRX
46
DELISTED
Veradigm Inc. Common Stock
MDRX
| $12.6M | 0.84% |
+839,521
| New | +$12.6M |
|
47
Novavax
NVAX
$1.21B
| $12M | 0.8% |
+66,402
| New | +$12M |
|
|
NVTA
48
DELISTED
Invitae Corporation
NVTA
| $11.6M | 0.77% |
+303,596
| New | +$11.6M |
|
49
Microsoft
MSFT
$3.78T
| $11.6M | 0.77% |
49,132
+1,057
| +2% | +$249K |
|
|
NBIS
50
Nebius Group N.V. Class A Ordinary Shares
NBIS
$15.5B
| $11.5M | 0.76% |
179,760
+32,300
| +22% | +$2.07M |
|